This module uses fundamental data of BioAge Labs, to approximate the value of its Beneish M Score. BioAge Labs, M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out BioAge Labs, Piotroski F Score and BioAge Labs, Altman Z Score analysis.
At present, BioAge Labs,'s Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Short Term Debt is expected to grow to about 47.3 M, whereas Short and Long Term Debt Total is forecasted to decline to about 28.9 M. At present, BioAge Labs,'s PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 33.21, whereas Price To Sales Ratio is forecasted to decline to 56.15.
At this time, it appears that BioAge Labs, is an unlikely manipulator. The earnings manipulation may begin if BioAge Labs,'s top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by BioAge Labs, executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of BioAge Labs,'s earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if BioAge Labs,'s auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between BioAge Labs,'s different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards BioAge Labs, in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find BioAge Labs,'s degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization
153,900
At present, BioAge Labs,'s Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting.
BioAge Labs, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioAge Labs,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioAge Labs,'s managers, analysts, and investors.
Environmental
Governance
Social
About BioAge Labs, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioAge Labs,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAge Labs, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAge Labs, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BioAge Labs, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs, Stock:
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.40)
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.